[
    {
        "other_ids": [],
        "amendment_date": null,
        "keywords": [
            "T-cell therapy",
            "immunotherapy"
        ],
        "dcp_id": null,
        "interventional_model": "Parallel",
        "lead_org": "Immatics US, Inc.",
        "eligibility": {
            "unstructured": [
                {
                    "inclusion_indicator": true,
                    "display_order": 0,
                    "description": "Patients must have recurrent/progressing and/or refractory solid tumors and must have received or not be eligible for all available indicated standard of care treatment."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 1,
                    "description": "Eastern Cooperative Oncology Group (ECOG) performance status 0-1"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 2,
                    "description": "HLA phenotype positive for the study"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 3,
                    "description": "Measurable disease according to RECIST 1.1"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 4,
                    "description": "Adequate selected organ function per protocol"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 5,
                    "description": "Patient's tumor must express tumor antigen by \"IMADetect\u00ae RT-qPCR"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 6,
                    "description": "Life expectancy more than 3 months"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 7,
                    "description": "Patients must have recurrent/progressing and/or refractory solid tumors and must have received or not be eligible for all available indicated standard of care treatment."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 8,
                    "description": "Female patient of childbearing potential must use adequate contraception prior to study entry until 12 months after the infusion of IMA203/IMA203CD8"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 9,
                    "description": "Male patient must agree to use effective contraception or be abstinent while on study and for 6 months after the infusion of IMA203/IMA203CD8"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 10,
                    "description": "The patient must have recovered from any side effects of prior therapy to Grade 1 or lower prior to lymphodepletion."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 11,
                    "description": "History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 12,
                    "description": "Pregnant or breastfeeding"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 13,
                    "description": "Serious autoimmune disease Note: At the discretion of the investigator, these patients may be included if their disease is well controlled without the use of immunosuppressive agents."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 14,
                    "description": "History of cardiac conditions as per protocol"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 15,
                    "description": "Prior stem cell transplantation or solid organ transplantation"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 16,
                    "description": "Concurrent severe and/or uncontrolled medical disease that could compromise participation in the study"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 17,
                    "description": "History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physician"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 18,
                    "description": "HIV infection, active hepatitis B virus (HBV), active hepatitis C virus (HCV) infection, ongoing active anti-HCV treatment or detectable HBV or HCV viral load at the most recent laboratory report. Patients with both HBV and HCV infections will be excluded from screening"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 19,
                    "description": "Patients who have received more than 4 prior systemic treatment lines for treatment of advanced and/or metastatic disease."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 20,
                    "description": "Patients who are known to have at least one single tumor lesion that exceeds 10 cm in diameter"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 21,
                    "description": "Any condition contraindicating leukapheresis, lymphodepletion, low-dose IL-2, and/or IMA203/IMA203CD8 treatment"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 22,
                    "description": "Patients with active brain metastases"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 23,
                    "description": "Concurrent participation in an interventional part of another clinical trial."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 24,
                    "description": "For nivolumab treatment, patients must not have a history of severe immune-related toxicities, defined as any Grade 3 or 4 toxicities related to prior PD1/PD-L1 inhibitor therapy (e.g., atezolizumab, pembrolizumab or nivolumab etc.)."
                }
            ],
            "structured": {
                "max_age": "999 Years",
                "max_age_number": 999.0,
                "min_age_unit": "Years",
                "max_age_unit": "Years",
                "max_age_in_years": 999.0,
                "gender": "BOTH",
                "accepts_healthy_volunteers": false,
                "min_age": "18 Years",
                "min_age_number": 18.0,
                "min_age_in_years": 18.0
            }
        },
        "completion_date_type_code": "ANTICIPATED",
        "detail_description": "SCREENING: Patient eligibility will be determined by protocol inclusion/exclusion criteria\r\n      including HLA (human leukocyte antigen) screening and a biopsy for biomarker screening. If\r\n      the patient is eligible, white blood cells will be taken during leukapheresis for the\r\n      manufacture of an IMA203 or an IMA203CD8 product.\r\n\r\n      MANUFACTURING: IMA203 and IMA203CD8 products will be made from the patients' white blood\r\n      cells.\r\n\r\n      TREATMENT: Lymphodepletion with cyclophosphamide and fludarabine will occur in the days\r\n      before the IMA203/IMA203CD8 product infusion to improve the duration of time that\r\n      IMA203/IMA203CD8 product stays in the body. The patient will be admitted to the hospital\r\n      during the T-cell infusion.\r\n\r\n      After the IMA203/IMA203CD8 product infusion, a low dose of IL-2 will be given subcutaneously\r\n      daily for 10 days.\r\n\r\n      In Extension Cohort B (IMA203) nivolumab will be administered intravenously.\r\n\r\n      Patients will be monitored closely throughout the study. The follow-up phase ends 5 years\r\n      post infusion.",
        "official_title": "Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors",
        "_phase_sort_order": 4,
        "collaborators": [],
        "associated_studies": [],
        "outcome_measures": [
            {
                "timeframe": "28 days",
                "name": "Determine the MTD and/or recommended dose for extension for IMA203/IMA203CD8",
                "description": "Number of patients with dose-limiting toxicities (DLTs)",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "35 days",
                "name": "Evaluate safety and tolerability of treatment with treatment with ACTengine\u00ae IMA203/IMA203CD8 products as monotherapy or in combination with nivolumab",
                "description": "Treatment emergent adverse events",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "up to 5 years post treatment",
                "name": "Persistence of T-cells",
                "description": "Measurement of TCR-engineered T cells in peripheral blood",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "up to 12 months",
                "name": "Tumor response",
                "description": "Immune-Related Response Evaluation Criteria In Solid Tumors (irRECIST)",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "up to 12 months",
                "name": "Tumor response",
                "description": "Response Evaluation Criteria In Solid Tumors (RECIST) 1.1",
                "type_code": "SECONDARY"
            }
        ],
        "phase": "I",
        "central_contact": {
            "phone": null,
            "name": null,
            "type": null,
            "email": null
        },
        "primary_purpose": "TREATMENT",
        "number_of_arms": 4,
        "_study_protocol_type_sort_order": 0,
        "nct_id": "NCT03686124",
        "biomarkers": [
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TRIAL",
                "synonyms": [
                    "HLA Positive",
                    "Human Leukocyte Antigen Phenotype Positive",
                    "Human Leukocyte Antigen Positive"
                ],
                "nci_thesaurus_concept_id": "C154157",
                "name": "HLA Phenotype Positive",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C3367",
                    "C77140",
                    "C35682",
                    "C36292"
                ],
                "parents": [
                    "C35682"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Observable Entity"
                ],
                "nci_thesaurus_concept_id": "C3367",
                "name": "Finding",
                "semantic_types": [
                    "Finding"
                ],
                "type": [
                    "branch"
                ],
                "ancestors": [],
                "parents": [],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Diagnostic Test Result",
                    "Test Result"
                ],
                "nci_thesaurus_concept_id": "C77140",
                "name": "Clinical Test Result",
                "semantic_types": [
                    "Finding"
                ],
                "type": [],
                "ancestors": [
                    "C3367"
                ],
                "parents": [
                    "C3367"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "LAB_RESULT",
                    "Lab Findings",
                    "Lab Value",
                    "Laboratory Finding",
                    "Laboratory Report",
                    "Labs",
                    "Test Result",
                    "test_result"
                ],
                "nci_thesaurus_concept_id": "C36292",
                "name": "Laboratory Test Result",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C3367",
                    "C77140"
                ],
                "parents": [
                    "C77140"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Positive",
                    "positive test result"
                ],
                "nci_thesaurus_concept_id": "C35682",
                "name": "Positive Laboratory Test Result",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C77140",
                    "C3367",
                    "C36292"
                ],
                "parents": [
                    "C36292"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            }
        ],
        "classification_code": null,
        "current_trial_status_date": "2019-05-01",
        "diseases": [
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": true,
                "synonyms": [
                    "Recurrent Solid Tumor",
                    "Relapsed Malignant Solid Neoplasm",
                    "Recurrent Malignant Solid Neoplasm",
                    "Relapsed Solid Neoplasm",
                    "Relapsed Solid Tumor",
                    "Recurrent Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C127153",
                "name": "Recurrent Malignant Solid Tumor",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C132146",
                    "C4813"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Refractory Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C133737",
                "name": "Refractory Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C132146",
                    "C120186"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Recurrence",
                    "Recurrent Cancer",
                    "Recurrent Malignant Tumor"
                ],
                "nci_thesaurus_concept_id": "C4813",
                "name": "Recurrent Malignant Neoplasm",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C4798",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm",
                    "Neoplasms, NOS",
                    "tumor",
                    "Neoplastic Growth",
                    "Tumor, NOS",
                    "Neoplasia",
                    "Neoplasm, NOS",
                    "Neoplastic Disease"
                ],
                "nci_thesaurus_concept_id": "C3262",
                "name": "Other Neoplasm",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C2991"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Solid Neoplasm",
                    "Solid Tumour",
                    "Solid tumor, NOS"
                ],
                "nci_thesaurus_concept_id": "C9292",
                "name": "Solid Tumor",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C7062",
                "name": "Neoplasm by Special Category",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C132146",
                "name": "Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9292",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "disease term",
                    "Diseases",
                    "Disease",
                    "Diseases and Disorders",
                    "disease_term",
                    "Diagnosis",
                    "Disease or Disorder, Non-Neoplastic",
                    "disease type",
                    "Disorders",
                    "Disease or Disorder",
                    "Disorder",
                    "condition",
                    "disease_type"
                ],
                "nci_thesaurus_concept_id": "C2991",
                "name": "Other Disease",
                "type": [
                    "maintype"
                ],
                "parents": []
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm Recurrence",
                    "Recurrence",
                    "Recurrent Tumor",
                    "Recurrent"
                ],
                "nci_thesaurus_concept_id": "C4798",
                "name": "Recurrent Neoplasm",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm, malignant",
                    "Cancer",
                    "Tumor, malignant, NOS",
                    "Malignancy",
                    "Unclassified tumor, malignant",
                    "Malignant Neoplastic Disease",
                    "Malignant Growth",
                    "CA",
                    "Malignant Tumor"
                ],
                "nci_thesaurus_concept_id": "C9305",
                "name": "Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Refractory Cancer",
                    "resistant cancer",
                    "clinical resistance"
                ],
                "nci_thesaurus_concept_id": "C120186",
                "name": "Refractory Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9305",
                    "C7628"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Refractory Tumor"
                ],
                "nci_thesaurus_concept_id": "C7628",
                "name": "Refractory Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            }
        ],
        "_primary_purpose_sort_order": 0,
        "protocol_id": "IMA203-101",
        "active_sites_count": 3,
        "lead_org_cancer_center": null,
        "arms": [
            {
                "interventions": [
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C141144",
                        "name": "Immune Checkpoint Modulator",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C308"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C161835",
                        "name": "IMADetect",
                        "description": null,
                        "type": "Device",
                        "category": "other",
                        "parents": [
                            "C16830"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1908",
                        "name": "Drug, Food, Chemical or Biomedical Material",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Drug Substance",
                            "Agent",
                            "Pharmacological Substance",
                            "Pharmacologic Agent",
                            "Pharmaceutical Agent",
                            "Pharmaceuticals",
                            "Drug"
                        ],
                        "nci_thesaurus_concept_id": "C1909",
                        "name": "Pharmacologic Substance",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C188985",
                        "name": "Autologous Anti-PRAME TCR/CD8alphabeta-expressing T-cells IMA203CD8",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent",
                        "parents": [
                            "C129826",
                            "C28681",
                            "C138180"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "ACT Agent",
                            "Adoptive Cellular Therapy Agent",
                            "Adoptive Cell Transfer Agent",
                            "Adoptive Cell-based Agent",
                            "Adoptive Cell Therapy Agent"
                        ],
                        "nci_thesaurus_concept_id": "C142078",
                        "name": "Adoptive Immunotherapy",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C308",
                            "C307"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antineoplastic Biological Response Modifier",
                            "Antineoplastic BRM",
                            "Anti-cancer Immunotherapeutic",
                            "Antineoplastic Immunotherapeutic"
                        ],
                        "nci_thesaurus_concept_id": "C129820",
                        "name": "Antineoplastic Immunomodulating Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C274",
                            "C308"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C143250",
                        "name": "Immune Checkpoint Inhibitor",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C141144"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Gene Therapy Agent"
                        ],
                        "nci_thesaurus_concept_id": "C1962",
                        "name": "Gene Therapy",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C307"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C161831",
                        "name": "Autologous PRAME-targeting TCR-engineered T-cells IMA203",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent",
                        "parents": [
                            "C129826",
                            "C28681",
                            "C138180"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "BRM",
                            "Immune Regulators",
                            "Immunopotentiators",
                            "Immune Mediators",
                            "Immunomodulators",
                            "Immunotherapeutic Agent",
                            "Immune Modulators",
                            "Biological Response Modifier",
                            "Immunotherapy Agent",
                            "Immunomodulating Agent",
                            "Biomodulators",
                            "Immunomodulatory Agent"
                        ],
                        "nci_thesaurus_concept_id": "C308",
                        "name": "Immunotherapy",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Opdivo"
                        ],
                        "nci_thesaurus_concept_id": "C68814",
                        "name": "Nivolumab",
                        "description": "A fully human monoclonal antibody directed against  the  negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity.  Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands PD-L1 and PD-L2, resulting in the activation of T-cells and cell-mediated  immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and effector function through the suppression of P13k/Akt pathway activation.  Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Biological/Vaccine",
                        "category": "agent",
                        "parents": [
                            "C129822",
                            "C128037"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C97325",
                        "name": "Manufactured Object",
                        "description": null,
                        "type": "Device",
                        "category": "other",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antineoplastic Drugs",
                            "Antineoplastics",
                            "Chemotherapeutic Agents, Neoplastic Disease",
                            "Antiproliferative Agents",
                            "Anti-Tumor Drugs",
                            "Anti-Cancer Agents",
                            "Cancer Drug",
                            "Anti-Tumor Agents",
                            "Tumor-Specific Treatment Agents",
                            "Antiproliferative Drugs"
                        ],
                        "nci_thesaurus_concept_id": "C274",
                        "name": "Antineoplastic Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Monoclonal Antibodies",
                            "Monoclonal Antibody"
                        ],
                        "nci_thesaurus_concept_id": "C20401",
                        "name": "Monoclonal Antibody Therapy",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C308",
                            "C307"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "PD-1 Inhibitor",
                            "Programmed Cell Death Protein 1 Inhibitor",
                            "Protein PD-1 Inhibitor",
                            "Anti-PD-1 Agent",
                            "PD-1-targeting Agent"
                        ],
                        "nci_thesaurus_concept_id": "C124946",
                        "name": "PD1 Inhibitor",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C163758",
                            "C143250"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Autologous T-cells"
                        ],
                        "nci_thesaurus_concept_id": "C28681",
                        "name": "Therapeutic Autologous Lymphocytes",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C142078"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Cell-based Gene Therapy Agent",
                            "Genetically-altered Immune Cell",
                            "Genetically-modified Immune Cell"
                        ],
                        "nci_thesaurus_concept_id": "C154231",
                        "name": "Genetically-engineered Immune Cell",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1962",
                            "C142078"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-PD-1 Monoclonal Antibody"
                        ],
                        "nci_thesaurus_concept_id": "C128037",
                        "name": "Anti-PD1 Monoclonal Antibody",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C124946",
                            "C20401"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anticancer Biological",
                            "Antineoplastic Biotherapeutic",
                            "Antineoplastic Biological",
                            "Anti-cancer Biological Agent"
                        ],
                        "nci_thesaurus_concept_id": "C129821",
                        "name": "Antineoplastic Biological Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C274",
                            "C307"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C62103",
                        "name": "Device",
                        "description": null,
                        "type": "Device",
                        "category": "other",
                        "parents": [
                            "C19238"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Hardware",
                            "Diagnostic, Therapeutic, and Research Equipment",
                            "Equipment"
                        ],
                        "nci_thesaurus_concept_id": "C19238",
                        "name": "Diagnostic, Therapeutic, or Research Equipment",
                        "description": null,
                        "type": "Device",
                        "category": "other",
                        "parents": [
                            "C97325"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Immunologic, Immunochemical",
                            "Biological Products",
                            "Biologics",
                            "Biologicals",
                            "Biopharmaceuticals",
                            "Immunologics"
                        ],
                        "nci_thesaurus_concept_id": "C307",
                        "name": "Biological Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Device",
                            "Medical Devices"
                        ],
                        "nci_thesaurus_concept_id": "C16830",
                        "name": "Medical Device",
                        "description": null,
                        "type": "Device",
                        "category": "other",
                        "parents": [
                            "C62103"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "TCR-engineered T-cells",
                            "T-cell Receptor-engineered T-lymphocytes",
                            "TCR T-cells",
                            "TCR T Cells",
                            "TCR-modified T Cells",
                            "T-cell Receptor-engineered T Cells"
                        ],
                        "nci_thesaurus_concept_id": "C138180",
                        "name": "T-cell Receptor-engineered T-cells",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C154231"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-cancer Immune Cell",
                            "Antineoplastic Immune Cells"
                        ],
                        "nci_thesaurus_concept_id": "C129826",
                        "name": "Antineoplastic Immune Cell",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C142078",
                            "C129821",
                            "C129820"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anticancer Antibody",
                            "Antineoplastic Ab",
                            "Anti-cancer Antibody"
                        ],
                        "nci_thesaurus_concept_id": "C129822",
                        "name": "Antineoplastic Antibody",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C129821"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Targeted Agent",
                            "Molecularly Targeted Therapy Agent",
                            "Anti-tumor Targeted Therapy Agent",
                            "Targeted Therapeutic Agent"
                        ],
                        "nci_thesaurus_concept_id": "C163758",
                        "name": "Targeted Therapy Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C274"
                        ]
                    }
                ],
                "name": "Arm not specified",
                "description": null,
                "type": null
            },
            {
                "interventions": [],
                "name": "Dose Escalation",
                "description": "Dose escalation of IMA203",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Extension Cohort A",
                "description": "IMA203 at RP2D",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Extension Cohort B",
                "description": "IMA203 at RP2D + nivolumab",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Extension Cohort C",
                "description": "IMA203CD8 at provisional RP2D",
                "type": "EXPERIMENTAL"
            }
        ],
        "study_model_code": null,
        "nci_id": "NCI-2019-03808",
        "why_study_stopped": null,
        "brief_summary": "The study purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products\r\n      with or without combination with nivolumab in patients with solid tumors that express\r\n      preferentially expressed antigen in melanoma (PRAME).",
        "brief_title": "ACTengine\u00ae IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors",
        "status_history": [
            {
                "status_date": "2019-05-01T00:00:00",
                "status": "ACTIVE"
            }
        ],
        "study_population_description": null,
        "sampling_method_code": null,
        "minimum_target_accrual_number": 102,
        "prior_therapy": [],
        "_current_trial_status_sort_order": 0,
        "start_date": "2019-05-14",
        "record_verification_date": "2023-02-01",
        "ctep_id": null,
        "current_trial_status": "Active",
        "study_model_other_text": null,
        "masking": {
            "role_caregiver": null,
            "masking": null,
            "role_investigator": null,
            "role_outcome_assessor": null,
            "role_subject": null,
            "allocation_code": "Non-Randomized Trial"
        },
        "acronym": "ACTengine",
        "nci_programs": [],
        "nci_funded": "Indirect",
        "anatomic_sites": [
            "Multiple"
        ],
        "ccr_id": null,
        "start_date_type_code": "ACTUAL",
        "principal_investigator": null,
        "study_source": "Industrial",
        "completion_date": "2028-12-01",
        "study_subtype_code": null,
        "study_protocol_type": "Interventional"
    }
]